Amplia enters clinical collaboration with Eli Lilly to test narmafotinib plus Lilly’s KRAS G12C inhibitor olomorasib in non-small cell lung cancer
The companies said they signed a Clinical Trial Collaboration and Supply Agreement to evaluate Amplia’s investigational FAK inhibitor narmafotinib in combination with Eli Lilly’s investigational KRAS G12C therapy olomorasib (marketed as Lumakras in the U.S.), in patients with non-small cell lung cancer.